Neurology

Compared with late postmenopausal women, menopausal hormone therapy (MHT) may influence certain Alzheimer disease-related biomarkers in early postmenopausal women.

Hallucinatory affects associated with psychedelic drugs and Lewy body diseases may have some commonalities.

New research confirms that calcium supplements do not increase dementia risk in older women, supporting their use for bone health without cognitive concerns.

BMS-986446 shows promise as a fast-tracked therapy for early Alzheimer disease, targeting tau protein to alter disease progression.

Adam Kahleifeh, PharmD, BCOP, discusses the impact of IDH mutations in low-grade gliomas.

New intravenous formulation GTx-104 shows promise in improving brain health outcomes for patients with aSAH, offering safer treatment options for pharmacists.

However, experts say that a causal relationship between acetaminophen and autism has not been established.

Selumetinib gains expanded FDA approval for younger pediatric patients with neurofibromatosis type 1 plexiform neurofibromas, enhancing treatment options and addressing significant disease-related challenges.

Both cemdisiran alone and combined with pozelimab improved the Myasthenia Gravis Activities of Daily Living score in patients with generalized myasthenia gravis.

FDA approves a new extended-release suspension formulation of risperidone for schizophrenia, expanding treatment options for patients.

The subcutaneous injection for maintenance treatment enhances accessibility and reduces infusion time for patients.

The new data highlight how dietary changes could fuel Alzheimer- and dementia-related mechanisms.

The complete response letter (CRL) stated that vatiquinone's new drug application (NDA) did not provide substantial evidence of efficacy and would need to be evaluated in a new trial.

Harvard researchers reveal lithium deficiency as a potential early driver of Alzheimer disease, suggesting new treatment avenues for patients.

The FDA approved fremanezumab for pediatric migraine prevention, offering a new treatment option for children and adolescents aged 6 to 17 years.

Hospitalized older adults infected with SARS-CoV-2 had faster declines in executive function and memory compared with both uninfected and nonhospitalized infected patients.

VMAT2 inhibitors can improve movement symptoms.

Amyvid is used for brain imaging to estimate amyloid plaque density in patients with cognitive impairment undergoing evaluation for Alzheimer disease.

A recent meta-analysis reveals low persistence rates with anti-dementia drugs, highlighting factors influencing adherence and the need for standardized reporting.

Results from a systematic review shed light on the role that obesity and overweight play in increasing the severity of symptoms in long COVID.

The authors wrote that a life course approach to the treatment and prevention of depression may help reduce individual burdens of dementia.

Integrating specialty pharmacists into neurology teams enhances patient care, medication management, and clinical outcomes for chronic conditions.

Juan Ovalles, MD, PhD, discusses how high placebo response rates driven by background therapy complicate lupus drug trials, and outlines evolving strategies in trial design, clinical practice, and pharmacist-led care to ensure investigational biologics are fairly evaluated and appropriately used in systemic lupus erythematosus.

Integrated health system specialty pharmacies can improve patient care for non–multiple sclerosis neurologic conditions.

The small molecule effectively blocks cell death effector proteins, potentially rescuing cells from degeneration.